- Report
- January 2025
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- January 2025
- 185 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- November 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
- 181 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- May 2024
- 182 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- July 2024
- 110 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- July 2024
- 150 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- June 2024
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- December 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- December 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- June 2024
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- June 2024
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- June 2024
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more